Embla Medical (EMBLA) CMD 2023 summary
Event summary combining transcript, slides, and related documents.
CMD 2023 summary
3 Mar, 2026Strategic direction and Growth'27 plan
Launched Growth'27, a five-year strategy focused on expanding patient reach, innovative solutions, and O&P value creation, aiming for accelerated organic growth and increased transparency.
Continued commitment to Bracing Simplified for injury care, emphasizing customer partnerships and streamlined product offerings.
Acquisitions will supplement organic growth, with a focus on market access, portfolio expansion, and technology.
Sustainability, people, and scalability remain foundational pillars, with enhanced reporting and segmentation.
New sales segmentation introduced to better reflect the evolving business mix and provide improved transparency.
Market position and business developments
Holds strong positions in prosthetics (#2 globally), bracing & supports (#4), and patient care (#3), with significant growth opportunities in emerging and developed markets.
Shifted business mix toward chronic mobility solutions, with divestments in non-core areas and acquisitions in patient care and prosthetics.
Direct presence expanded to 17 emerging and 22 developed markets, with 90% of sales from developed markets.
Majority of O&P channel patients have lifelong chronic mobility challenges, driving recurring sales and service needs.
Enhanced patient reach through new care models, digital engagement, and functional trade-up strategies in both developed and emerging markets.
Innovation and product development
Innovation strategy centers on patient-centric solutions with proven clinical efficacy, focusing on prosthetics and chronic mobility challenges.
Recent innovations include advanced socket solutions, increased bionic penetration, and AeroFit® breathable liners to address clinical challenges.
Ongoing R&D investment outpaces sales growth, with a robust pipeline targeting higher fitting rates and functional upgrades.
Future efforts include AI, machine learning, and mind-controlled prosthetics, as well as wearable robotics for stroke rehabilitation.
Preparing for data-driven, customized healthcare solutions and expanding into new chronic categories.
Latest events from Embla Medical
- Record sales, innovation, and emerging market expansion drive strong growth outlook.EMBLA
Life Science-dagen 202613 Mar 2026 - Strong 2025 growth and profit drive a robust 2026 outlook with higher margins expected.EMBLA
Q4 20253 Feb 2026 - 2025 delivered strong growth and cash flow; 2026 guidance targets 5-8% organic growth, 20-22% margin.EMBLA
Q4 20253 Feb 2026 - Record Q2 sales, 22% EBITDA margin, and new bionic launches set up future growth.EMBLA
Q2 20243 Feb 2026 - Medicare expansion boosts access to advanced prosthetics and drives growth opportunities.EMBLA
Status Update22 Jan 2026 - Q3 delivered 7% organic sales growth, 22% EBITDA margin, and strong EMEA-driven results.EMBLA
Q3 202419 Jan 2026 - Record sales and margin growth fueled by innovation and global expansion in mobility solutions.EMBLA
SEB Nordic Seminar presentation15 Jan 2026 - Growth, acquisitions, and U.S. Medicare changes position for strong 2025 performance.EMBLA
Status Update12 Jan 2026 - Advanced neuro orthotics drive growth, high margins, and improved mobility for patients.EMBLA
Status Update12 Jan 2026